Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 133 results found. Search for [ Central Drugs Standard Control Organisation ]

Results 1 to 21 of 133
BusinessToday.In
January 11, 2021
Pfizer is yet to submit additional data sought by India authorities regarding its COVID-19 vaccine for granting emergency use approval to it; the company has missed last three SEC meetings too


BusinessToday.In
January 7, 2021
COVID-19 vaccination drive: This development comes after the government said that the vaccine would be rolled out 10 days after the date of approval for emergency use


PTI
January 5, 2021
This daunting challenge is not only for India but also for all the governments across the globe as they start inoculating their populations to tackle the pandemic, noted Dr Soumya Swaminathan, Chief Scientist of WHO


BusinessToday.In
January 4, 2021
Bharat Biotech's Chairman and Managing Director Dr. Krishna Ella, in a press conference on Monday, January 5, clarified that its vaccine is safe and the company is conducting trials in over 12 countries besides India


BusinessToday.In
January 4, 2021
Cadila Healthcare share touched an intraday high of Rs 492.95, rising 3.02% against previous close of Rs 478.50 on BSE


BusinessToday.In
January 4, 2021
The phase-2 trials of Zydus Cadila's coronavirus vaccine had been conducted in around 1,000 healthy adults


BusinessToday.In
January 3, 2021
The ICMR head emphasised that the scientists at ICMR have been successfully able to culture the UK strain and the efficacy of Covaxin against it will be further tested in days to come


BusinessToday.In
January 3, 2021
PM Modi thanked doctors, medical staff, police personnel, sanitation workers and all corona warriors for their hard work during the coronavirus outbreak


BusinessToday.In
January 3, 2021
COVID-19 vaccines in India: Oxford-AstraZeneca's coronavirus vaccine Covishield and Bharat Biotech's COVID vaccine Covaxin will be India's first vaccines


BusinessToday.In
January 3, 2021
Coronavirus vaccine trials: Bharat Biotech said that it is steadily moving towards its goal of 26,000 volunteers. Phase 3 of human clinical trials for Covaxin began in mid-November


BusinessToday.In
January 2, 2021
The SEC has recommended Covaxin for emergency use authorisation; the recommendation, along with rollout modalities, will now be taken up by the DCGI for a final decision on the matter


BusinessToday.In
January 2, 2021
Covishield DCGI approval: Pune-based Serum Institute will have to provide safety, efficacy and immunogenicity data from the ongoing clinical trials in India and globally


BusinessToday.In
January 2, 2021
Coronavirus vaccination drive: The task force has added 31 COVID-19 vaccine hubs that will supply vaccines to 29,000 vaccination points


BusinessToday.In
January 1, 2021
Covishield has become the first coronavirus vaccine to receive a regulatory nod in India. Now, Drug Controller General of India (DCGI) will take a final call on rolling out the inoculation


BusinessToday.In
January 1, 2021
Reports suggest that an expert panel will meet to take up the application for emergency use of the three vaccines


BusinessToday.In
December 30, 2020
The expert committee on COVID-19 analysed the additional data and information that it had asked from SII and Bharat Biotech earlier this month


BusinessToday.In
December 30, 2020
This development comes hours after the UK government accepted the recommendation from the Medicines and Healthcare Regulatory Agency (MHRA) to authorise Oxford University-AstraZeneca's Covid-19 vaccine, named Covishield, for emergency use


BusinessToday.In
December 27, 2020
COVID-19 vaccination drive: The mock drill will be like the actual vaccination drive but there will be no vaccine administration. Data will be fed to the Co-WIN app, cold storage will be tested and vaccine transportation from cold storage to the sites, crowd management etc will be checked


PTI
December 27, 2020
Serum Institute of India (SII) has made a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine. The SII has already manufactured 40 million doses of the vaccine


BusinessToday.In
December 26, 2020
Pune-based SII is to submit an updated safety data of phase 2 and 3 clinical trials in India, immunogenicity data from the clinical trial in the UK and India, as well as the assessment results of the UK Medicines and Healthcare products Regulatory Agency


PAGES 1 OF 7  12345